We are hiring

“We are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners. Far too often, we have heard about the industry’s dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics”